{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T01:30:00Z","timestamp":1791855000908,"version":"4.3.4"},"reference-count":172,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T00:00:00Z","timestamp":1712102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Institute of General Medical Sciences (NIGMS) Center of Biomedical Research Excellence (COBRE)","award":["2P20 GM109024"],"award-info":[{"award-number":["2P20 GM109024"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Neurodegenerative disorders (NDs) have become increasingly common during the past three decades. Approximately 15% of the total population of the world is affected by some form of NDs, resulting in physical and cognitive disability. The most common NDs include Alzheimer\u2019s disease, Parkinson\u2019s disease, amyotrophic lateral sclerosis, and Huntington\u2019s disease. Although NDs are caused by a complex interaction of genetic, environmental, and lifestyle variables, neuroinflammation is known to be associated with all NDs, often leading to permanent damage to neurons of the central nervous system. Furthermore, numerous emerging pieces of evidence have demonstrated that inflammation not only supports the progression of NDs but can also serve as an initiator. Hence, various medicines capable of preventing or reducing neuroinflammation have been investigated as ND treatments. While anti-inflammatory medicine has shown promising benefits in several preclinical models, clinical outcomes are often questionable. In this review, we discuss various NDs with their current treatment strategies, the role of neuroinflammation in the pathophysiology of NDs, and the use of anti-inflammatory agents as a potential therapeutic option.<\/jats:p>","DOI":"10.3390\/ijms25073995","type":"journal-article","created":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T08:42:34Z","timestamp":1712133754000},"page":"3995","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":119,"title":["Neuroinflammation in Neurodegenerative Disorders: Current Knowledge and Therapeutic Implications"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-2039-4864","authenticated-orcid":false,"given":"Paras Mani","family":"Giri","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences, School of Pharmacy, College of Health and Human Sciences, North Dakota State University, Fargo, ND 58105, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anurag","family":"Banerjee","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, School of Pharmacy, College of Health and Human Sciences, North Dakota State University, Fargo, ND 58105, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arpita","family":"Ghosal","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, School of Pharmacy, College of Health and Human Sciences, North Dakota State University, Fargo, ND 58105, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2457-7619","authenticated-orcid":false,"given":"Buddhadev","family":"Layek","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, School of Pharmacy, College of Health and Human Sciences, North Dakota State University, Fargo, ND 58105, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,4,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Vlamos, P., Kotsireas, I.S., and Tarnanas, I. (2020). Handbook of Computational Neurodegeneration, Springer International Publishing.","DOI":"10.1007\/978-3-319-75479-6"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Mor\u00e9n, C., deSouza, R.M., Giraldo, D.M., and Uff, C. (2022). Antioxidant Therapeutic Strategies in Neurodegenerative Diseases. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23169328"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"72","DOI":"10.32607\/20758251-2010-2-1-72-80","article-title":"Calcium signaling and neurodegeneration","volume":"2","author":"Bezprozvanny","year":"2010","journal-title":"Acta Naturae"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S1474-4422(19)30411-9","article-title":"The global burden of neurological disorders: Translating evidence into policy","volume":"19","author":"Feigin","year":"2020","journal-title":"Lancet Neurol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"(2023). 2023 Alzheimer\u2019s disease facts and figures. Alzheimers Dement., 19, 1598\u20131695.","DOI":"10.1002\/alz.13016"},{"key":"ref_6","unstructured":"(2024, February 28). Parkinson\u2019s Disease: Challenges, Progress, and Promise | National Institute of Neurological Disorders and Stroke, Available online: https:\/\/www.ninds.nih.gov\/current-research\/focus-disorders\/parkinsons-disease-research\/parkinsons-disease-challenges-progress-and-promise."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/agm2.12243","article-title":"Neurodegenerative disorders: Assessing the impact of natural vs drug-induced treatment options","volume":"6","author":"Mathur","year":"2023","journal-title":"Aging Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.neurobiolaging.2018.11.018","article-title":"Impairment in complex activities of daily living is related to neurodegeneration in Alzheimer\u2019s disease\u2013specific regions","volume":"75","author":"Jutten","year":"2019","journal-title":"Neurobiol. Aging"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jab.2016.02.002","article-title":"Speech and language impairments in dementia","volume":"14","author":"Klimova","year":"2016","journal-title":"J. Appl. Biomed."},{"key":"ref_10","first-page":"1401","article-title":"Alzheimer\u2019s disease and language impairments: Social intervention and medical treatment","volume":"10","author":"Klimova","year":"2015","journal-title":"Clin. Interv. Aging"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Gupta, S., McColl, M.A., Guilcher, S.J.T., and Smith, K. (2019). Managing Medication Cost Burden: A Qualitative Study Exploring Experiences of People with Disabilities in Canada. Int. J. Environ. Res. Public Health, 16.","DOI":"10.3390\/ijerph16173066"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"15132","DOI":"10.18632\/oncotarget.23738","article-title":"The genes associated with early-onset Alzheimer\u2019s disease","volume":"9","author":"Dai","year":"2018","journal-title":"Oncotarget"},{"key":"ref_13","unstructured":"Adam, M.P., Feldman, J., Mirzaa, G.M., Pagon, R.A., Wallace, S.E., Bean, L.J.H., Gripp, K.W., and Amemiya, A. (1993). GeneReviews\u00ae, University of Washington, Seattle."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"837579","DOI":"10.3389\/ftox.2022.837579","article-title":"Role of Environmental Toxicants on Neurodegenerative Disorders","volume":"4","author":"Nabi","year":"2022","journal-title":"Front. Toxicol."},{"key":"ref_15","first-page":"376","article-title":"Oxidative stress in neurodegenerative diseases","volume":"7","author":"Chen","year":"2012","journal-title":"Neural Regen. Res."},{"key":"ref_16","first-page":"452270","article-title":"Neuroinflammation as a Common Feature of Neurodegenerative Disorders","volume":"10","author":"Maccioni","year":"2019","journal-title":"Front. Pharmacol."},{"key":"ref_17","unstructured":"(2024, February 26). Links Found between Viruses and Neurodegenerative Diseases, Available online: https:\/\/www.nih.gov\/news-events\/nih-research-matters\/links-found-between-viruses-neurodegenerative-diseases."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"394","DOI":"10.4103\/1673-5374.266045","article-title":"Dietary habits, lifestyle factors and neurodegenerative diseases","volume":"15","author":"Dumitrascu","year":"2020","journal-title":"Neural Regen. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"804","DOI":"10.3945\/an.117.016261","article-title":"Nutritional Factors Affecting Adult Neurogenesis and Cognitive Function","volume":"8","author":"Poulose","year":"2017","journal-title":"Adv. Nutr."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Pardo-Moreno, T., Gonz\u00e1lez-Acedo, A., Rivas-Dom\u00ednguez, A., Garc\u00eda-Morales, V., Garc\u00eda-Cozar, F.J., Ramos-Rodr\u00edguez, J.J., and Melguizo-Rodr\u00edguez, L. (2022). Therapeutic Approach to Alzheimer\u2019s Disease: Current Treatments and New Perspectives. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14061117"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2174\/1567205013666151218150322","article-title":"Defining the earliest pathological changes of Alzheimer\u2019s disease","volume":"13","author":"Vickers","year":"2016","journal-title":"Curr. Alzheimer Res."},{"key":"ref_22","unstructured":"Kumar, A., Sidhu, J., Goyal, A., and Tsao, J.W. (2024). StatPearls, StatPearls Publishing."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Ma, C., Hong, F., and Yang, S. (2022). Amyloidosis in Alzheimer\u2019s Disease: Pathogeny, Etiology, and Related Therapeutic Directions. Molecules, 27.","DOI":"10.3390\/molecules27041210"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"5541","DOI":"10.2147\/IJN.S200490","article-title":"Alzheimer\u2019s disease: Pathogenesis, diagnostics, and therapeutics","volume":"14","author":"Tiwari","year":"2019","journal-title":"Int. J. Nanomed."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3934\/Neuroscience.2019.4.273","article-title":"\u03b2-Amyloid precursor protein (APP) and the human diseases","volume":"6","author":"Nguyen","year":"2019","journal-title":"AIMS Neurosci."},{"key":"ref_26","unstructured":"(2024, February 22). How Is Alzheimer\u2019s Disease Treated?, Available online: https:\/\/www.nia.nih.gov\/health\/alzheimers-treatment\/how-alzheimers-disease-treated."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1179573520907397","DOI":"10.1177\/1179573520907397","article-title":"Current and Future Treatments in Alzheimer Disease: An Update","volume":"12","author":"Yiannopoulou","year":"2020","journal-title":"J. Cent. Nerv. Syst. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s10072-016-2546-5","article-title":"Dysfunction of NMDA receptors in Alzheimer\u2019s disease","volume":"37","author":"Zhang","year":"2016","journal-title":"Neurol. Sci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"746","DOI":"10.2174\/156720512801322564","article-title":"N-methyl D-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer\u2019s disease, vascular dementia and Parkinson\u2019s disease","volume":"9","author":"Olivares","year":"2012","journal-title":"Curr. Alzheimer Res."},{"key":"ref_30","unstructured":"(2024, February 22). Treatments for Behavior. Available online: https:\/\/www.alz.org\/alzheimers-dementia\/treatments\/treatments-for-behavior."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1001\/jamaneurol.2023.3810","article-title":"Brexpiprazole for the Treatment of Agitation in Alzheimer Dementia: A Randomized Clinical Trial","volume":"80","author":"Lee","year":"2023","journal-title":"JAMA Neurol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.euroneuro.2015.01.014","article-title":"Potentiation of neurite outgrowth by brexpiprazole, a novel serotonin-dopamine activity modulator: A role for serotonin 5-HT1A and 5-HT2A receptors","volume":"25","author":"Ishima","year":"2015","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s40259-023-00633-2","article-title":"Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer\u2019s Disease","volume":"38","author":"Cummings","year":"2024","journal-title":"BioDrugs"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s13195-022-01124-2","article-title":"Lecanemab in patients with early Alzheimer\u2019s disease: Detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study","volume":"14","author":"McDade","year":"2022","journal-title":"Alzheimers Res. Ther."},{"key":"ref_35","first-page":"31925","article-title":"Aducanumab, a Novel Anti-Amyloid Monoclonal Antibody, for the Treatment of Alzheimer\u2019s Disease: A Comprehensive Review","volume":"10","author":"Haddad","year":"2022","journal-title":"Health Psychol. Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"873","DOI":"10.3233\/ADR-230025","article-title":"Antibody-Mediated Clearance of Brain Amyloid-\u03b2: Mechanisms of Action, Effects of Natural and Monoclonal Anti-A\u03b2 Antibodies, and Downstream Effects","volume":"7","author":"Loeffler","year":"2023","journal-title":"J. Alzheimers Dis. Rep."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41577-022-00684-6","article-title":"Inflammation and immune dysfunction in Parkinson disease","volume":"22","author":"Tansey","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13024-019-0332-6","article-title":"Impaired dopamine metabolism in Parkinson\u2019s disease pathogenesis","volume":"14","author":"Masato","year":"2019","journal-title":"Mol. Neurodegener."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1001\/archneur.60.3.337","article-title":"Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases","volume":"60","author":"Zarow","year":"2003","journal-title":"Arch. Neurol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/mds.25095","article-title":"Neuronal vulnerability, pathogenesis, and Parkinson\u2019s disease","volume":"28","author":"Sulzer","year":"2013","journal-title":"Mov. Disord."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Zhu, H., Lemos, H., Bhatt, B., Islam, B.N., Singh, A., Gurav, A., Huang, L., Browning, D.D., Mellor, A., and Fulzele, S. (2017). Carbidopa, a drug in use for management of Parkinson disease inhibits T cell activation and autoimmunity. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0183484"},{"key":"ref_42","first-page":"37","article-title":"Side effects of a dopamine agonist therapy for Parkinson\u2019s disease: A mini-review of clinical pharmacology","volume":"89","author":"Borovac","year":"2016","journal-title":"Yale J. Biol. Med."},{"key":"ref_43","first-page":"477","article-title":"Monoamine Oxidase-B Inhibitors for the Treatment of Parkinson\u2019s Disease: Past, Present, and Future","volume":"12","author":"Tan","year":"2022","journal-title":"J. Park. Dis."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1017\/S031716710000007X","article-title":"COMT inhibitors in Parkinson\u2019s disease","volume":"26","author":"Rivest","year":"1999","journal-title":"Can. J. Neurol. Sci. J. Can. Des Sci. Neurol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1080\/14737175.2021.1968298","article-title":"Redefining the strategy for the use of COMT inhibitors in Parkinson\u2019s disease: The role of opicapone","volume":"21","author":"Jenner","year":"2021","journal-title":"Expert Rev. Neurother."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1750-1172-4-3","article-title":"Amyotrophic lateral sclerosis","volume":"4","author":"Wijesekera","year":"2009","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/nrneurol.2014.184","article-title":"The phenotypic variability of amyotrophic lateral sclerosis","volume":"10","author":"Swinnen","year":"2014","journal-title":"Nat. Rev. Neurol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1111\/ene.14393","article-title":"Amyotrophic lateral sclerosis: A clinical review","volume":"27","author":"Masrori","year":"2020","journal-title":"Eur. J. Neurol."},{"key":"ref_49","first-page":"49","article-title":"The genetics of amyotrophic lateral sclerosis: Current insights","volume":"6","author":"Alsultan","year":"2016","journal-title":"Degener. Neurol. Neuromuscul. Dis."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"497022","DOI":"10.3389\/fnins.2019.01310","article-title":"ALS Genetics, Mechanisms, and Therapeutics: Where Are We Now?","volume":"13","author":"Mejzini","year":"2019","journal-title":"Front. Neurosci."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3892\/ijo.2021.5275","article-title":"Riluzole: A neuroprotective drug with potential as a novel anti-cancer agent (Review)","volume":"59","author":"Blyufer","year":"2021","journal-title":"Int. J. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2217\/nmt-2020-0033","article-title":"Riluzole for the treatment of amyotrophic lateral sclerosis","volume":"10","author":"Saitoh","year":"2020","journal-title":"Neurodegener. Dis. Manag."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e01795","DOI":"10.1002\/brb3.1795","article-title":"Amyotrophic lateral sclerosis care in Saudi Arabia: A survey of providers\u2019 perceptions","volume":"10","author":"Abuzinadah","year":"2020","journal-title":"Brain Behav."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s40265-023-01904-6","article-title":"Tofersen: First Approval","volume":"83","author":"Blair","year":"2023","journal-title":"Drugs"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"11795735221092517","DOI":"10.1177\/11795735221092517","article-title":"Current and Possible Future Therapeutic Options for Huntington\u2019s Disease","volume":"14","author":"Ferguson","year":"2022","journal-title":"J. Cent. Nerv. Syst. Dis."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/B978-0-12-381328-2.00014-6","article-title":"Genetics and neuropathology of Huntington\u2019s disease","volume":"98","author":"Reiner","year":"2011","journal-title":"Int. Rev. Neurobiol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/ng0893-387","article-title":"Trinucleotide repeat length instability and age of onset in Huntington\u2019s disease","volume":"4","author":"Duyao","year":"1993","journal-title":"Nat. Genet."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1021\/acsmedchemlett.3c00415","article-title":"Highly Potent Peptide Therapeutics To Prevent Protein Aggregation in Huntington\u2019s Disease","volume":"14","author":"Khan","year":"2023","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"4604","DOI":"10.1073\/pnas.96.8.4604","article-title":"Self-assembly of polyglutamine-containing huntingtin fragments into amyloid-like fibrils: Implications for Huntington\u2019s disease pathology","volume":"96","author":"Scherzinger","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_60","first-page":"378","article-title":"Huntington\u2019s disease: Clinical and aetiologic aspects","volume":"157","author":"Wider","year":"2006","journal-title":"Schweiz. Arch. F\u00fcr Neurol. Und Psychiatr. = Arch. Suisses Neurol. Psychiatr. = Swiss Arch. Neurol. Psychiatry"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMcibr067022","article-title":"Huntington\u2019s disease\u2013making connections","volume":"356","author":"Greenamyre","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.biocel.2010.10.014","article-title":"Huntington\u2019s disease: From molecular basis to therapeutic advances","volume":"43","author":"Krobitsch","year":"2011","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/WCO.0b013e328304b692","article-title":"Pathophysiology of Huntington\u2019s disease: From huntingtin functions to potential treatments","volume":"21","author":"Roze","year":"2008","journal-title":"Curr. Opin. Neurol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S0140-6736(07)60111-1","article-title":"Huntington\u2019s disease","volume":"369","author":"Walker","year":"2007","journal-title":"Lancet"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/ajmg.a.38494","article-title":"Therapy development in Huntington disease: From current strategies to emerging opportunities","volume":"176","author":"Dickey","year":"2018","journal-title":"Am. J. Med. Genet. A"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1345\/aph.1M582","article-title":"Role of tetrabenazine for Huntington\u2019s disease-associated chorea","volume":"44","author":"Poon","year":"2010","journal-title":"Ann. Pharmacother."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1586\/14737175.6.1.7","article-title":"Tetrabenazine in the treatment of hyperkinetic movement disorders","volume":"6","author":"Kenney","year":"2006","journal-title":"Expert Rev. Neurother."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/ana.410120308","article-title":"Tetrabenazine has properties of a dopamine receptor antagonist","volume":"12","author":"Login","year":"1982","journal-title":"Ann. Neurol."},{"key":"ref_69","first-page":"515","article-title":"Tetrabenazine, an amine-depleting drug, also blocks dopamine receptors in rat brain","volume":"225","author":"Reches","year":"1983","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s40265-016-0670-4","article-title":"Current Pharmacological Approaches to Reduce Chorea in Huntington\u2019s Disease","volume":"77","author":"Coppen","year":"2017","journal-title":"Drugs"},{"key":"ref_71","first-page":"690","article-title":"Tetrabenazine (Xenazine), An FDA-Approved Treatment Option For Huntington\u2019s Disease-Related Chorea","volume":"33","author":"Yero","year":"2008","journal-title":"Pharm. Ther. Peer-Rev. J. Formul. Manag."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40734-017-0051-5","article-title":"Indirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease","volume":"4","author":"Claassen","year":"2017","journal-title":"J. Clin. Mov. Disord."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Kim, A., Lalonde, K., Truesdell, A., Gomes Welter, P., Brocardo, P.S., Rosenstock, T.R., and Gil-Mohapel, J. (2021). New Avenues for the Treatment of Huntington\u2019s Disease. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22168363"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2165\/00003495-199753020-00007","article-title":"Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses","volume":"53","author":"Fulton","year":"1997","journal-title":"Drugs"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1176\/jnp.17.4.496","article-title":"Depression and stages of Huntington\u2019s disease","volume":"17","author":"Paulsen","year":"2005","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"ref_76","unstructured":"(2024). Medications for Memory, Cognition and Dementia-Related Behaviors, Alzheimer\u2019s Association."},{"key":"ref_77","first-page":"e128408","article-title":"Donepezil Beyond Alzheimer\u2019s Disease? A Narrative Review of Therapeutic Potentials of Donepezil in Different Diseases","volume":"21","author":"Pooladgar","year":"2022","journal-title":"Iran. J. Pharm. Res. IJPR"},{"key":"ref_78","unstructured":"Brunton, L.L., and Knollmann, B.C. (2023). Goodman & Gilman\u2019s: The Pharmacological Basis of Therapeutics, McGraw-Hill Education. [14th ed.]."},{"key":"ref_79","first-page":"Cd001191","article-title":"Rivastigmine for Alzheimer\u2019s disease","volume":"9","author":"Birks","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_80","unstructured":"(2024). Prescription Medications, Parkinson\u2019s Foundation. [2024th ed.]."},{"key":"ref_81","unstructured":"Ozery, M., and Wadhwa, R. (2024, March 26). Bromocriptine, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK555948\/."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1177\/10600280231172802","article-title":"Sodium Phenylbutyrate and Taurursodiol: A New Therapeutic Option for the Treatment of Amyotrophic Lateral Sclerosis","volume":"58","author":"Alqallaf","year":"2024","journal-title":"Ann. Pharmacother."},{"key":"ref_83","unstructured":"Cerillo, J.L., and Parmar, M. (2024, March 26). Tofersen, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK594270\/."},{"key":"ref_84","unstructured":"Loscalzo, J., Fauci, A., Kasper, D., Hauser, S., Longo, D., and Jameson, J.L. (2022). Harrison\u2019s Principles of Internal Medicine, 21e, McGraw-Hill Education."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"36040","DOI":"10.52965\/001c.36040","article-title":"deutetrabenazine for the treatment of chorea associated with Huntington\u2019s disease","volume":"10","author":"Gupta","year":"2022","journal-title":"Health Psychol. Res."},{"key":"ref_86","first-page":"69","article-title":"Short-Term Effects of Olanzapine in Huntington Disease","volume":"14","author":"Squitieri","year":"2001","journal-title":"Cogn. Behav. Neurol."},{"key":"ref_87","first-page":"e9748","article-title":"Management of Agitation in Huntington\u2019s Disease: A Review of the Literature","volume":"12","author":"Rossi","year":"2020","journal-title":"Cureus"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/mds.25750","article-title":"Results of the citalopram to enhance cognition in Huntington disease trial","volume":"29","author":"Beglinger","year":"2014","journal-title":"Mov. Disord."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1007\/s002130000575","article-title":"Fluoxetine in the treatment of Huntington\u2019s disease","volume":"153","author":"Daniele","year":"2001","journal-title":"Psychopharmacology"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s11940-010-0088-3","article-title":"Treatment of Irritability in Huntington\u2019s Disease","volume":"12","year":"2010","journal-title":"Curr. Treat. Options Neurol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.clinbiochem.2019.04.001","article-title":"Neuro-inflammation and anti-inflammatory treatment options for Alzheimer\u2019s disease","volume":"72","author":"Ozben","year":"2019","journal-title":"Clin. Biochem."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s13024-018-0299-8","article-title":"Advances in developing novel therapeutic strategies for Alzheimer\u2019s disease","volume":"13","author":"Cao","year":"2018","journal-title":"Mol. Neurodegener."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S1474-4422(15)70016-5","article-title":"Neuroinflammation in Alzheimer\u2019s disease","volume":"14","author":"Heneka","year":"2015","journal-title":"Lancet Neurol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"4283","DOI":"10.1523\/JNEUROSCI.4814-07.2008","article-title":"Dynamics of the microglial\/amyloid interaction indicate a role in plaque maintenance","volume":"28","author":"Bolmont","year":"2008","journal-title":"J. Neurosci. Off. J. Soc. Neurosci."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1002\/glia.23074","article-title":"Microglia contributes to plaque growth by cell death due to uptake of amyloid \u03b2 in the brain of Alzheimer\u2019s disease mouse model","volume":"64","author":"Baik","year":"2016","journal-title":"Glia"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.trci.2018.06.014","article-title":"Inflammation as a central mechanism in Alzheimer\u2019s disease","volume":"4","author":"Kinney","year":"2018","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/alzrt24","article-title":"Inflammation in Alzheimer\u2019s disease: Relevance to pathogenesis and therapy","volume":"2","author":"Zotova","year":"2010","journal-title":"Alzheimers Res. Ther."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"fcaa109","DOI":"10.1093\/braincomms\/fcaa109","article-title":"Anti-inflammatories in Alzheimer\u2019s disease-potential therapy or spurious correlate?","volume":"2","author":"Mather","year":"2020","journal-title":"Brain Commun."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"24939","DOI":"10.1038\/srep24939","article-title":"Fingolimod modulates multiple neuroinflammatory markers in a mouse model of Alzheimer\u2019s disease","volume":"6","author":"Aytan","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1093\/brain\/aww117","article-title":"Cyclooxygenase inhibition targets neurons to prevent early behavioural decline in Alzheimer\u2019s disease model mice","volume":"139","author":"Woodling","year":"2016","journal-title":"Brain"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s13073-021-00983-y","article-title":"Identification and drug-induced reversion of molecular signatures of Alzheimer\u2019s disease onset and progression in AppNL-G-F, AppNL-F, and 3xTg-AD mouse models","volume":"13","author":"Pauls","year":"2021","journal-title":"Genome Med."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1177\/1535370215576313","article-title":"Parkinson\u2019s disease and enhanced inflammatory response","volume":"240","author":"Stojkovska","year":"2015","journal-title":"Exp. Biol. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.neuint.2012.12.016","article-title":"Neuroinflammation and oxidative stress: Co-conspirators in the pathology of Parkinson\u2019s disease","volume":"62","author":"Taylor","year":"2013","journal-title":"Neurochem. Int."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"580311","DOI":"10.3389\/fnins.2020.580311","article-title":"Parkinson\u2019s Disease: Can Targeting Inflammation Be an Effective Neuroprotective Strategy?","volume":"14","author":"Gundersen","year":"2021","journal-title":"Front. Neurosci."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s10048-006-0077-6","article-title":"The medial and lateral substantia nigra in Parkinson\u2019s disease: mRNA profiles associated with higher brain tissue vulnerability","volume":"8","author":"Duke","year":"2007","journal-title":"Neurogenetics"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1002\/ana.24396","article-title":"Traumatic brain injury in later life increases risk for Parkinson disease","volume":"77","author":"Gardner","year":"2015","journal-title":"Ann. Neurol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.alit.2023.07.005","article-title":"Association of allergic disease with Parkinson\u2019s disease: A nationally representative retrospective cohort study","volume":"73","author":"Nam","year":"2024","journal-title":"Allergol. Int."},{"key":"ref_108","first-page":"393769","article-title":"Peripheral Inflammation Increases the Damage in Animal Models of Nigrostriatal Dopaminergic Neurodegeneration: Possible Implication in Parkinson\u2019s Disease Incidence","volume":"2011","author":"Machado","year":"2011","journal-title":"Park. Dis."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"51647","DOI":"10.1074\/jbc.M407328200","article-title":"Neurotoxic Effects of Lipopolysaccharide on Nigral Dopaminergic Neurons Are Mediated by Microglial Activation, Interleukin-1\u03b2, and Expression of Caspase-11 in Mice","volume":"279","author":"Arai","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1289\/ehp.1003013","article-title":"Neuroinflammation and \u03b1-synuclein dysfunction potentiate each other, driving chronic progression of neurodegeneration in a mouse model of Parkinson\u2019s disease","volume":"119","author":"Gao","year":"2011","journal-title":"Environ. Health Perspect."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s40035-015-0042-0","article-title":"Neuroinflammation in Parkinson\u2019s disease and its potential as therapeutic target","volume":"4","author":"Wang","year":"2015","journal-title":"Transl. Neurodegener."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1212\/WNL.0b013e31820f2d79","article-title":"Use of ibuprofen and risk of Parkinson disease","volume":"76","author":"Gao","year":"2011","journal-title":"Neurology"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.intimp.2004.05.006","article-title":"Dexamethasone protects against dopaminergic neurons damage in a mouse model of Parkinson\u2019s disease","volume":"4","author":"Litwin","year":"2004","journal-title":"Int. Immunopharmacol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"14669","DOI":"10.1073\/pnas.251341998","article-title":"Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson\u2019s disease","volume":"98","author":"Du","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1124\/jpet.106.106351","article-title":"Interleukin-10 protects lipopolysaccharide-induced neurotoxicity in primary midbrain cultures by inhibiting the function of NADPH oxidase","volume":"319","author":"Qian","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.neuropharm.2015.05.014","article-title":"Characterizations of a synthetic pituitary adenylate cyclase-activating polypeptide analog displaying potent neuroprotective activity and reduced in vivo cardiovascular side effects in a Parkinson\u2019s disease model","volume":"108","author":"Lamine","year":"2016","journal-title":"Neuropharmacology"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"769","DOI":"10.2165\/11316780-000000000-00000","article-title":"NSAID use and the risk of Parkinson\u2019s disease: Systematic review and meta-analysis of observational studies","volume":"26","author":"Samii","year":"2009","journal-title":"Drugs Aging"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1212\/WNL.0b013e3181d5a4a3","article-title":"Anti-inflammatory drugs and risk of Parkinson disease: A meta-analysis","volume":"74","author":"Gagne","year":"2010","journal-title":"Neurology"},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"NINDS NET-PD Investigators (2006). A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology, 66, 664\u2013671.","DOI":"10.1212\/01.wnl.0000201252.57661.e1"},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"NINDS NET-PD Investigators (2008). A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month results. Clin. Neuropharmacol., 31, 141\u2013150.","DOI":"10.1097\/WNF.0b013e3181342f32"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1007\/s12640-019-00038-6","article-title":"Anti-inflammatory Activity of Ursolic Acid in MPTP-Induced Parkinsonian Mouse Model","volume":"36","author":"Rai","year":"2019","journal-title":"Neurotox. Res."},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Siracusa, R., Scuto, M., Fusco, R., Trovato, A., Ontario, M.L., Crea, R., Di Paola, R., Cuzzocrea, S., and Calabrese, V. (2020). Anti-inflammatory and Anti-oxidant Activity of Hidrox\u00ae in Rotenone-Induced Parkinson\u2019s Disease in Mice. Antioxidants, 9.","DOI":"10.3390\/antiox9090824"},{"key":"ref_123","first-page":"537","article-title":"Neuroinflammation in motor neuron disease","volume":"77","author":"Komine","year":"2015","journal-title":"Nagoya J. Med. Sci."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1111\/j.1582-4934.2008.00430.x","article-title":"Cyclooxygenase in normal human tissues\u2014Is COX-1 really a constitutive isoform, and COX-2 an inducible isoform?","volume":"13","author":"Zidar","year":"2009","journal-title":"J. Cell. Mol. Med."},{"key":"ref_125","first-page":"573","article-title":"Non-steroidal anti-inflammatory drugs and amyotrophic lateral sclerosis: Results from five prospective cohort studies","volume":"13","author":"Fondell","year":"2012","journal-title":"Amyotroph. Lateral Scler. Off. Publ. World Fed. Neurol. Res. Group. Mot. Neuron Dis."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1006\/exnr.1998.6984","article-title":"Beneficial effects of lysine acetylsalicylate, a soluble salt of aspirin, on motor performance in a transgenic model of amyotrophic lateral sclerosis","volume":"155","author":"Curet","year":"1999","journal-title":"Exp. Neurol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"14759","DOI":"10.1038\/s41598-020-71813-1","article-title":"The effectiveness of nonsteroidal anti-inflammatory drugs and acetaminophen in reduce the risk of amyotrophic lateral sclerosis? A meta-analysis","volume":"10","author":"Chang","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/ana.20903","article-title":"Trial of celecoxib in amyotrophic lateral sclerosis","volume":"60","author":"Cudkowicz","year":"2006","journal-title":"Ann. Neurol."},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Post, J., Kogel, V., Schaffrath, A., Lohmann, P., Shah, N.J., Langen, K.J., Willbold, D., Willuweit, A., and Kutzsche, J. (2021). A Novel Anti-Inflammatory d-Peptide Inhibits Disease Phenotype Progression in an ALS Mouse Model. Molecules, 26.","DOI":"10.3390\/molecules26061590"},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Ketabforoush, A.H.M.E., Chegini, R., Barati, S., Tahmasebi, F., Moghisseh, B., Joghataei, M.T., Faghihi, F., and Azedi, F. (2023). Masitinib: The promising actor in the next season of the Amyotrophic Lateral Sclerosis treatment series. Biomed. Pharmacother., 160.","DOI":"10.1016\/j.biopha.2023.114378"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/21678421.2019.1632346","article-title":"Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: A randomized clinical trial","volume":"21","author":"Mora","year":"2020","journal-title":"Amyotroph. Lateral Scler. Front. Degener."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/s41392-023-01486-5","article-title":"Role of neuroinflammation in neurodegeneration development","volume":"8","author":"Zhang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S0072-9752(07)01256-0","article-title":"Neuropathology of Huntington\u2019s disease","volume":"89","author":"Vonsattel","year":"2008","journal-title":"Handb. Clin. Neurol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/jnen\/60.2.161","article-title":"Early and progressive accumulation of reactive microglia in the Huntington disease brain","volume":"60","author":"Sapp","year":"2001","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1097\/WNR.0b013e32832e34ee","article-title":"Distinct neuroinflammatory profile in post-mortem human Huntington\u2019s disease","volume":"20","author":"Silvestroni","year":"2009","journal-title":"Neuroreport"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1093\/hmg\/ddq212","article-title":"In vivo expression of polyglutamine-expanded huntingtin by mouse striatal astrocytes impairs glutamate transport: A correlation with Huntington\u2019s disease subjects","volume":"19","author":"Faideau","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Shehata, N.I., Abd El-Salam, D.M., Hussein, R.M., and Rizk, S.M. (2023). Effect of safranal or candesartan on 3-nitropropionicacid-induced biochemical, behavioral and histological alterations in a rat model of Huntington\u2019s disease. PLoS ONE, 18.","DOI":"10.1371\/journal.pone.0293660"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1093\/brain\/awp239","article-title":"Microglial CB2 cannabinoid receptors are neuroprotective in Huntington\u2019s disease excitotoxicity","volume":"132","author":"Palazuelos","year":"2009","journal-title":"Brain"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1111\/j.1460-9568.2007.05717.x","article-title":"Cannabidiol reduced the striatal atrophy caused 3-nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors","volume":"26","author":"Sagredo","year":"2007","journal-title":"Eur. J. Neurosci."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/brain\/awq278","article-title":"Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington\u2019s disease","volume":"134","author":"Blazquez","year":"2011","journal-title":"Brain"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1002\/glia.20838","article-title":"Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: Relevance for Huntington\u2019s disease","volume":"57","author":"Sagredo","year":"2009","journal-title":"Glia"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.neuropharm.2006.06.013","article-title":"The cannabinoid receptor agonist WIN 55,212-2 attenuates the effects induced by quinolinic acid in the rat striatum","volume":"51","author":"Pintor","year":"2006","journal-title":"Neuropharmacology"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/0091-3057(91)90386-G","article-title":"Controlled clinical trial of cannabidiol in Huntington\u2019s disease","volume":"40","author":"Consroe","year":"1991","journal-title":"Pharmacol. Biochem. Behav."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3233\/JHD-170283","article-title":"Cannabinoids for Treatment of Dystonia in Huntington\u2019s Disease","volume":"7","author":"Saft","year":"2018","journal-title":"J. Huntingt. Dis."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s12640-012-9315-x","article-title":"Targeting neuro-inflammatory cytokines and oxidative stress by minocycline attenuates quinolinic-acid-induced Huntington\u2019s disease-like symptoms in rats","volume":"22","author":"Kalonia","year":"2012","journal-title":"Neurotox. Res."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.bbadis.2005.11.002","article-title":"Combination therapy using minocycline and coenzyme Q10 in R6\/2 transgenic Huntington\u2019s disease mice","volume":"1762","author":"Stack","year":"2006","journal-title":"Biochim. Biophys. Acta (BBA)\u2014Mol. Basis Dis."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1080\/10717544.2021.1937383","article-title":"Repurposing ibuprofen-loaded microemulsion for the management of Alzheimer\u2019s disease: Evidence of potential intranasal brain targeting","volume":"28","author":"Wen","year":"2021","journal-title":"Drug Deliv."},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Ribeiro, T.d.C., S\u00e1bio, R.M., Luiz, M.T., de Souza, L.C., Fonseca-Santos, B., Cides da Silva, L.C., Fantini, M.C.d.A., Planeta, C.d.S., and Chorilli, M. (2022). Curcumin-Loaded Mesoporous Silica Nanoparticles Dispersed in Thermo-Responsive Hydrogel as Potential Alzheimer Disease Therapy. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14091976"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mcn.2017.12.003","article-title":"Trans \u03b5-viniferin is an amyloid-\u03b2 disaggregating and anti-inflammatory drug in a mouse primary cellular model of Alzheimer\u2019s disease","volume":"88","author":"Vion","year":"2018","journal-title":"Mol. Cell. Neurosci."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"174695","DOI":"10.1016\/j.ejphar.2021.174695","article-title":"Naproxen as a potential candidate for promoting rivastigmine anti-Alzheimer activity against aluminum chloride-prompted Alzheimer\u2019s-like disease in rats; neurogenesis and apoptosis modulation as a possible underlying mechanism","volume":"915","author":"Hussein","year":"2022","journal-title":"Eur. J. Pharmacol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.bmc.2018.01.030","article-title":"Design, synthesis and evaluation of 4\u2032-OH-flurbiprofen-chalcone hybrids as potential multifunctional agents for Alzheimer\u2019s disease treatment","volume":"26","author":"Cao","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"108378","DOI":"10.1016\/j.neuropharm.2020.108378","article-title":"Celecoxib promotes survival and upregulates the expression of neuroprotective marker genes in two different in vitro models of Parkinson\u2019s disease","volume":"194","author":"Dassati","year":"2021","journal-title":"Neuropharmacology"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.neuroscience.2012.11.006","article-title":"Anti-inflammatory properties rather than anti-oxidant capability is the major mechanism of neuroprotection by sodium salicylate in a chronic rotenone model of Parkinson\u2019s disease","volume":"231","author":"Thakur","year":"2013","journal-title":"Neuroscience"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"110820","DOI":"10.1016\/j.cbi.2023.110820","article-title":"Baicalin exerts neuroprotective actions by regulating the Nrf2-NLRP3 axis in toxin-induced models of Parkinson\u2019s disease","volume":"387","author":"Huang","year":"2024","journal-title":"Chem.-Biol. Interact."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"155309","DOI":"10.1016\/j.phymed.2023.155309","article-title":"Rubusoside mitigates neuroinflammation and cellular apoptosis in Parkinson\u2019s disease, and alters gut microbiota and metabolite composition","volume":"124","author":"Meng","year":"2024","journal-title":"Phytomedicine"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"176234","DOI":"10.1016\/j.ejphar.2023.176234","article-title":"Harnessing the neuroprotective effect of oral administration of benfotiamine in MPTP induced Parkinson\u2019s disease in rats","volume":"962","author":"Bashir","year":"2024","journal-title":"Eur. J. Pharmacol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"175498","DOI":"10.1016\/j.ejphar.2023.175498","article-title":"Linagliptin counteracts rotenone\u2019s toxicity in non-diabetic rat model of Parkinson\u2019s disease: Insights into the neuroprotective roles of DJ-1, SIRT-1\/Nrf-2 and implications of HIF1-\u03b1","volume":"941","author":"ElGamal","year":"2023","journal-title":"Eur. J. Pharmacol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1007\/s13311-023-01444-7","article-title":"Therapeutic Effects of Combination of Nebivolol and Donepezil: Targeting Multifactorial Mechanisms in ALS","volume":"20","author":"Lee","year":"2023","journal-title":"Neurotherapeutics"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/s12974-016-0620-9","article-title":"Post-paralysis tyrosine kinase inhibition with masitinib abrogates neuroinflammation and slows disease progression in inherited amyotrophic lateral sclerosis","volume":"13","author":"Trias","year":"2016","journal-title":"J. Neuroinflamm."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1007\/s13311-016-0462-2","article-title":"Fingolimod: A Disease-Modifier Drug in a Mouse Model of Amyotrophic Lateral Sclerosis","volume":"13","author":"Potenza","year":"2016","journal-title":"Neurotherapeutics"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s11064-023-04083-8","article-title":"Azilsartan Attenuates 3-Nitropropinoic Acid-Induced Neurotoxicity in Rats: The Role of I\u0138B\/NF-\u0138B and KEAP1\/Nrf2 Signaling Pathways","volume":"49","author":"Hamouda","year":"2024","journal-title":"Neurochem. Res."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"113655","DOI":"10.1016\/j.ejmech.2021.113655","article-title":"Silyl resveratrol derivatives as potential therapeutic agents for neurodegenerative and neurological diseases","volume":"223","author":"Delgado","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1189957","DOI":"10.3389\/fphar.2023.1189957","article-title":"Neuroprotective potency of mangiferin against 3-nitropropionic acid induced Huntington\u2019s disease-like symptoms in rats: Possible antioxidant and anti-inflammatory mechanisms","volume":"14","author":"Lum","year":"2023","journal-title":"Front. Pharmacol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/s41593-018-0236-8","article-title":"Animal models of neurodegenerative diseases","volume":"21","author":"Dawson","year":"2018","journal-title":"Nat. Neurosci."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1084\/jem.20182042","article-title":"All (animal) models (of neurodegeneration) are wrong. Are they also useful?","volume":"215","author":"Ransohoff","year":"2018","journal-title":"J. Exp. Med."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s40035-020-00221-2","article-title":"Neuroinflammation in neurodegenerative disorders: The roles of microglia and astrocytes","volume":"9","author":"Kwon","year":"2020","journal-title":"Transl. Neurodegener."},{"key":"ref_167","doi-asserted-by":"crossref","unstructured":"Joshi, H.P., Jo, H.-J., Kim, Y.-H., An, S.-B., Park, C.-K., and Han, I. (2021). Stem Cell Therapy for Modulating Neuroinflammation in Neuropathic Pain. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22094853"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.4103\/1673-5374.221171","article-title":"Roles of neural stem cells in the repair of peripheral nerve injury","volume":"12","author":"Wang","year":"2017","journal-title":"Neural Regen. Res."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"876","DOI":"10.4103\/1673-5374.249236","article-title":"Neural stem cell transplantation inhibits glial cell proliferation and P2X receptor-mediated neuropathic pain in spinal cord injury rats","volume":"14","author":"Du","year":"2019","journal-title":"Neural Regen. Res."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1159\/000509268","article-title":"Mesenchymal Stem Cells: A Potential Therapeutic Strategy for Neurodegenerative Diseases","volume":"83","author":"Yao","year":"2020","journal-title":"Eur. Neurol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"1900043","DOI":"10.1002\/adtp.201900043","article-title":"Nanoengineering of Mesenchymal Stem Cells via Surface Modification for Efficient Cancer Therapy","volume":"2","author":"Layek","year":"2019","journal-title":"Adv. Ther."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.bbr.2017.10.032","article-title":"Resveratrol promotes hUC-MSCs engraftment and neural repair in a mouse model of Alzheimer\u2019s disease","volume":"339","author":"Wang","year":"2018","journal-title":"Behav. Brain Res."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/7\/3995\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:22:59Z","timestamp":1760106179000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/7\/3995"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,3]]},"references-count":172,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["ijms25073995"],"URL":"https:\/\/doi.org\/10.3390\/ijms25073995","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,3]]}}}